Su Fu
Vice President, Corporate Development at Architect Therapeutics
Su Fu
Vice President, Corporate Development at Architect Therapeutics
San Francisco, California
Overview
Work Experience
Vice President, Corporate Development
2023 - Current
Precision chemical editing platform for drugging tough targets. Foundational science from Yu Lab and Cravatt Lab. Series A led by ARCH.
Interim - Vice President, Business Development
2022 - 2023
RNA medicines to treat human disease in ways that were not previously possible.
Senior Associate
2021 - 2023
Build disruptive lifescience companies.
Market Development & Strategic Alliance
2017 - 2021
Early hire on the CBO/COO team, roles spanning product strategy, partnering, alliance, and IPO/financing to advance medicines against HBV, Flu, HIV, COVID-19, including Sotrovimab (EUA 2021).
Venture Creation, University of Chicago Innovation Fund
2015 - 2017
Partnered with PIs and industry executives to identify, validate, and develop promising university technologies for commercialization.
Associate, Investment Team
2012 - 2015
THL Credit is an alternative asset manager with $3 billion under management and an affiliate of Thomas H. Lee Partners.
Investment Banking Analyst
2011 - 2012
Healthcare, Leveraged Finance
Investment Banking Analyst
2010 - 2011
Global Chemicals Group - Biofuels, Renewables, Agrochemicals, and Petrochemicals.